MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer.
Ibiayi Dagogo-JackSatoshi YodaJochen K LennerzAdam LangenbucherJessica J LinMarguerite M RooneyKylie Prutisto-ChangAudris OhNathaniel A AdamsBeow Y YeapEmily ChinAndrew DoHetal D MarbleSara E StevensSubba R DigumarthyAshish SaxenaRebecca J NagyCyril H BenesChristopher G AzzoliMichael S LawrenceJustin F GainorAlice T ShawAaron N HataPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
Treatment with next-generation ALK inhibitors, particularly in the first-line setting, may lead to MET-driven resistance. Patients with acquired MET alterations may derive clinical benefit from therapies that target both ALK and MET.